B.Riley reiterates Kymera Therapeutics stock rating on new trial data
Investing.com Canada
B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (NASDAQ: KYMR) after the company presented new data from its oral STAT6 degrader KT-621 at EADV’26. The stock has seen a 104% increase over the past year, reflecting strong investor interest. Several other analysts, including Stifel, BofA Securities, Guggenheim, and Piper Sandler, have also recently increased their price targets and maintained Buy or Overweight ratings, indicating broad positive sentiment driv
Read the full story
This is a short summary. The complete article is published by Investing.com Canada.
Headline and summary aggregated from public news feeds. For information only — not financial advice.